Literature DB >> 21524587

Synthesis and evaluation of carbaborane derivatives of indomethacin as cyclooxygenase inhibitors.

Matthias Scholz1, Anna L Blobaum, Lawrence J Marnett, Evamarie Hey-Hawkins.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological activities by inhibiting cyclooxygenase (COX)-1 and COX-2. Previous studies have shown that esters and amides of non-selective inhibitors such as indomethacin are selective against COX-2, which is the therapeutically relevant isoform. Structure-activity analysis indicates that substituted phenyl rings are tolerated as ester components. In the present study, the introduction of inorganic ortho- and meta-carbaborane moieties was explored with the aim to create COX-2 inhibitors and more importantly to investigate the validity of using these boron clusters as drug entities. Interestingly, only the ortho-carbaborane ester was active whereas the meta isomer was not. A similar lack of inhibitory potency was observed when an adamantyl substituent or alkylene spacers at the carbaborane were introduced in the ester functionality.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524587      PMCID: PMC3401020          DOI: 10.1016/j.bmc.2011.03.054

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  28 in total

1.  Adenosine and 2'-deoxyadenosine modified with boron cluster pharmacophores as new classes of human blood platelet function modulators.

Authors:  Katarzyna Bednarska; Agnieszka B Olejniczak; Błazej A Wojtczak; Zofia Sułowska; Zbigniew J Leśnikowski
Journal:  ChemMedChem       Date:  2010-05-03       Impact factor: 3.466

Review 2.  COX-2 as a target for cancer chemotherapy.

Authors:  Nilanjan Ghosh; Rituparna Chaki; Vivekananda Mandal; Subhash C Mandal
Journal:  Pharmacol Rep       Date:  2010 Mar-Apr       Impact factor: 3.024

3.  Protein kinase C modulators bearing dicarba-CLOSO-dodecaborane as a hydrophobic pharmacophore.

Authors:  Y Endo; T Yoshimi; K Kimura; A Itai
Journal:  Bioorg Med Chem Lett       Date:  1999-09-06       Impact factor: 2.823

4.  C-Hydroxydicarba-closo-dodecaboranes.

Authors:  Ilya Zharov; Anil Saxena; Josef Michl; Robert D. Miller
Journal:  Inorg Chem       Date:  1997-12-17       Impact factor: 5.165

5.  Carbaboranes as pharmacophores: similarities and differences between aspirin and asborin.

Authors:  Matthias Scholz; Goran N Kaluđerović; Harish Kommera; Reinhard Paschke; Joanna Will; William S Sheldrick; Evamarie Hey-Hawkins
Journal:  Eur J Med Chem       Date:  2011-01-28       Impact factor: 6.514

Review 6.  Cyclooxygenases: structural and functional insights.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

7.  Crystal and molecular structure of an antiinflammatory agent, indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid.

Authors:  T J Kistenmacher; R E Marsh
Journal:  J Am Chem Soc       Date:  1972-02-23       Impact factor: 15.419

8.  Preparation and evaluation of carborane analogues of tamoxifen.

Authors:  Michael L Beer; Jennifer Lemon; John F Valliant
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

Review 9.  The synthesis and use of boronated amino acids for boron neutron capture therapy.

Authors:  George W Kabalka; Min-Liang Yao
Journal:  Anticancer Agents Med Chem       Date:  2006-03       Impact factor: 2.505

10.  Facile and efficient synthesis of C-hydroxycarboranes and C,C'-dihydroxycarboranes.

Authors:  Kiminori Ohta; Tokuhito Goto; Hiroto Yamazaki; Fabio Pichierri; Yasuyuki Endo
Journal:  Inorg Chem       Date:  2007-04-13       Impact factor: 5.165

View more
  7 in total

1.  Ortho-carbaborane derivatives of indomethacin as cyclooxygenase (COX)-2 selective inhibitors.

Authors:  Matthias Scholz; Anna L Blobaum; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  Bioorg Med Chem       Date:  2012-06-05       Impact factor: 3.641

2.  nido-Dicarbaborate Induces Potent and Selective Inhibition of Cyclooxygenase-2.

Authors:  Wilma Neumann; Shu Xu; Menyhárt B Sárosi; Matthias S Scholz; Brenda C Crews; Kebreab Ghebreselasie; Surajit Banerjee; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2015-06-18       Impact factor: 3.466

3.  2-Carbaborane-3-phenyl-1H-indoles--synthesis via McMurry reaction and cyclooxygenase (COX) inhibition activity.

Authors:  Markus Laube; Wilma Neumann; Matthias Scholz; Peter Lönnecke; Brenda Crews; Lawrence J Marnett; Jens Pietzsch; Torsten Kniess; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2013-01-09       Impact factor: 3.466

4.  Preclinical Pharmacokinetics and Acute Toxicity in Rats of 5-{[(2E)-3-Bromo-3-carboxyprop-2-enoyl]amino}-2-hydroxybenzoic Acid: A Novel 5-Aminosalicylic Acid Derivative with Potent Anti-Inflammatory Activity.

Authors:  Mara Gutiérrez-Sánchez; Aurelio Romero-Castro; José Correa-Basurto; Martha Cecilia Rosales-Hernández; Itzia Irene Padilla-Martínez; Jessica Elena Mendieta-Wejebe
Journal:  Molecules       Date:  2021-11-11       Impact factor: 4.411

5.  Carboranyl Analogues of Mefenamic Acid and Their Biological Evaluation.

Authors:  Liridona Useini; Marija Mojić; Markus Laube; Peter Lönnecke; Jonas Dahme; Menyhárt B Sárosi; Sanja Mijatović; Danijela Maksimović-Ivanić; Jens Pietzsch; Evamarie Hey-Hawkins
Journal:  ACS Omega       Date:  2022-06-29

6.  Interactions of Boron Clusters and their Derivatives with Serum Albumin.

Authors:  Tomasz M Goszczyński; Krzysztof Fink; Konrad Kowalski; Zbigniew J Leśnikowski; Janusz Boratyński
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

7.  Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.

Authors:  Antonio Buzharevski; Svetlana Paskaš; Menyhárt-Botond Sárosi; Markus Laube; Peter Lönnecke; Wilma Neumann; Blagoje Murganić; Sanja Mijatović; Danijelа Maksimović-Ivanić; Jens Pietzsch; Evamarie Hey-Hawkins
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.